There is 1 paper on GAFAD in aging research: 1 observational study in people.
1 paper studies it1 finding
“In the external validation cohort, GAFAD similarly outperformed GALAD, achieving a higher AUC (0.874 vs. 0.841, P<0.05), greater sensitivity (72% vs. 57%), and improved accuracy (82% vs. 75%) at 90% specificity.”
- Humans1
Effects
1Hepatocellular carcinoma detection
upin humans1
1 study
Hepatocellular carcinoma detection
upin humans1
GAFAD is linked with better hepatocellular carcinoma detection in external validation cohort (HBV-, HCV-related and non-viral etiologies) (AUC 0.874 vs. 0.841, P<0.05).
“In the external validation cohort, GAFAD similarly outperformed GALAD, achieving a higher AUC (0.874 vs. 0.841, P<0.05), greater sensitivity (72% vs. 57%), and improved accuracy (82% vs. 75%) at 90% specificity.”
Humansin external validation cohort (HBV-, HCV-related and non-viral etiologies)
Clinical and molecular hepatology
Latest
1 paper in 12 monthsClinical and Molecular Hepatology
GAFAD: A liquid chromatography-tandem mass spectrometry-based model for early hepatocellular carcinoma detection beyond GALAD's limitations
Cohort study in peopleHepatocellular carcinoma